Brief: Regeneron Pharmaceuticals Announces Positive Phase 3 NIMBLE Trial Results For Cemdisiran In gMG
21/04/2026 18:34
April 21 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: CEMDISIRAN, DOSED SUBCUTANEOUSLY EVERY 12 WEEKS, DEMONSTRATES RAPID, DEEP AND SUSTAINED DISEASE CONTROL IN GENERALIZED MYASTHENIA GRAVIS (GMG) PHASE 3 TRIAL REGENERON PHARMACEUTICALS INC - ANNOUNCES POSITIVE PHASE 3 NIMBLE TRIAL RESULTS FOR CEMDISIRAN IN GMG Source text: ID:nGNX6xB5d5 Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement